导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.78% | 1512/4773 |
| 近一周 | -2.48% | 2311/5462 |
| 近一月 | -4.80% | 2764/5421 |
| 近一季 | -8.66% | 2897/5209 |
| 近半年 | -6.21% | 3040/4920 |
| 近一年 | 7.75% | 1264/4366 |
| 近两年 | 68.75% | 1001/2954 |
| 近三年 | 35.73% | 839/2253 |
| 成立以来 | 52.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.83% 1167/4961 |
18.57% 1364/5312 |
- - |
- - |
| 2025 | 30.53% 1309/4813 |
1.99% 1499/3635 |
1.81% 2115/4076 |
24.40% 1472/4524 |
1.05% 1565/4813 |
| 2024 | 6.13% 1784/3463 |
-2.40% 1358/2808 |
-5.03% 1622/3014 |
15.87% 1606/3129 |
-1.18% 1615/3463 |
| 2023 | -5.86% 788/2656 |
7.48% 570/2280 |
-4.06% 1033/2385 |
-4.43% 1139/2515 |
-4.47% 1049/2655 |
| 2022 | -18.36% 699/2207 |
-13.55% 779/1919 |
2.66% 1272/2016 |
-10.44% 403/2113 |
2.71% 857/2208 |
| 2021 | 16.78% 258/1822 |
-1.37% 479/1255 |
9.63% 541/1330 |
4.47% 347/1466 |
3.37% 446/1822 |
| 2020 | 21.89% 683/1250 |
-3.87% 326/1028 |
16.12% 456/1067 |
6.10% 875/1164 |
2.92% 957/1184 |
| 2019 | 24.33% 620/1092 |
30.00% 262/739 |
-9.66% 679/788 |
0.10% 559/850 |
5.75% 681/918 |
| 2018 | -30.67% 473/834 |
- - |
-12.75% 407/631 |
-7.11% 433/660 |
-12.18% 419/682 |
| 2017 | 0.57% 475/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证500ETF联接C VS. 长安沪深300非周期A(740101) |